Assessing the Emerging Role of Checkpoint Inhibition and Other Immune Therapies in Lymphoma

Release Date: September 7, 2016
Expiration Date: September 7, 2017
Media: Print with online posttest, evaluation, and request for credit


This activity is designed to inform physicians about the emerging role of checkpoint inhibition and other immune therapies in the treatment of lymphoma. 

Instructions for Participation/How to Receive Credit:

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, "educational content/video" will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit.  Participants may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This activity is directed toward hematologists, medical oncologists, nurses, and nurse practitioners who manage and treat patients with lymphoma. Surgical oncologists, radiation oncologists, pathologists, fellows, physician assistants, and other healthcare providers interested in the treatment of lymphoma are also invited to participate. 

Learning Objectives

After participating in this CME/CE activity, learners should be better prepared to:
  • Describe the unmet needs in the treatment of patients with
  • Review recent developments in the field of immunology with re-
    spect to lymphoma treatment
  • Review current and emerging clinical trial information concerning
    the use of investigational immunotherapeutic approaches for lym- phoma treatment 

The American Journal of Hematology/ Oncology® Editorial Board

Debu Tripathy, MD
Professor and Chairman
Department of Breast Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosure: Grant/research support from Genentech/Roche, Pfizer, Puma Biotechnology Inc, and Novartis (clinical trial support contracted to the University of Southern California and MD Anderson Cancer Cen- ter); consultant for Eisai, OncoPlex Diagnostics, Merck, and Novartis. 


Anas Younes, MD

Professor and Chief, Lymphoma Service 
Division of Hematologic Oncology 
Memorial Sloan Kettering Cancer Center 
New York, New York, USA 
Disclosure:Grant/research Support: Novartis, Johnson & Johnson, Curis; Other: Honorarium from: Bayer; Bristol-Myers Squibb, Celgene, Janssen, Sanofi, Seattle Genetics,Takeda, Millennium 



Staff/Planner Disclosures and Conflict of Interest Resolution

The staff of Physicians’ Education Resource®, LLC (PER®), and the edi- torial staff of The American Journal of Hematology/Oncology® have no relevant financial relationships with commercial interests to disclose.
It is the policy of PER® to ensure fair balance, independence, objec- tivity, and scientific objectivity in all of our CME/CE activities. In ac- cordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity. 

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accredita- tion Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring ma- terial for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 1.0 Contact Hour. 

Acknowledgment of Commercial Support

This activity is funded by Physicians' Education Resource®, LLC.

Off-Label Disclosure and Disclaimer

This continuing medical and nursing education activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed.The information provided in this CME/CE activity is for continuing medical and nursing education purposes only andis not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, and management options for a specific patient’s medical condition. 


The opinions expressed in the content are solely those of the individ- ual faculty members and do not reflect those of Physicians’ Education Resource®, LLC. 

Contact information for questions about the activity:

Physicians’ Education Resource®, LLC 666 Plainsboro Road, Suite 356 Plainsboro, NJ 08536
Phone: (888) 949-0045

Hardware And Software Requirements

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)
  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
Minimum System Requirements (Mac OS)
  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Become a Member

Forgot Password?
Calendar of Events
Filter By